Changes to the Code
H.R. 5316 · Drug Shortage Compounding Patient Access Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 353a Pharmacy compounding
6 changes the bill asks for here, 5 carried out
- Carried out:
in paragraph (1), by striking
or
at the end; - Carried out:
in paragraph (2)(B)(ii)(II), by striking the period at the end and inserting
; or
; and - Carried out:
by adding at the end the following:
(3) notwithstanding the requirement in the matter preceding paragraph (1) that the drug product is compounded for an identified individual patient based on a valid prescription order or notation described in such matter, is by a licensed pharmacist or licensed physician and the …
- Carried out:
Paragraph (2) of section 503A(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a(b)(2)) is amended to read as follows:
(2) Definition.— For purposes of paragraph (1)(D), the term “essentially a copy of a commercially available drug product” does not include— (A) a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant …
- Not carried out:
by striking subsection (b)(3)(B) and the matter following such subsection and inserting the following:
(B) such drug product is labeled as follows: “This medication has been compounded for dispensing to an individual patient and has not been approved by the Food and Drug Administration”.; and
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking subsection (X) (X) (X) and the matter following such subsection and inserting the following: QCONTENT; and - Carried out:
in subsection (b)(1)(A)(i)(I) by striking
National Formulary monograph
and insertingNational Formulary drug or dietary supplement monograph
.
§ 353a(a)In general(1)–(2)
Start of § 353a to (a)(1) unchanged ·
(A) a licensed pharmacist in a State licensed pharmacy or a Federal facility, or
(B) a licensed physician,
on the prescription order for such individual patient made by a licensed physician or other licensed practitioner authorized by State law to prescribe drugs;[struck: or]
(2)
(A) is by a licensed pharmacist or licensed physician in limited quantities before the receipt of a valid prescription order for such individual patient; and
§ 353a(a)–(b)
(a)(2)(B) unchanged ·
(I) such individual patient for whom the prescription order will be provided; or
(II) the physician or other licensed practitioner who will write such prescription order[struck: .][inserted: ; or]
(3) [inserted: notwithstanding the requirement in the matter preceding paragraph (1) that the drug product is compounded for an identified individual patient based on a valid prescription order or notation described in such matter, is by a licensed pharmacist or licensed physician and the compounded drug product is compounded for distribution in limited quantities to a licensed prescriber for urgent administration to a patient in a hospital or other clinical setting, provided that all of the following are met:]
(A) [inserted: The drug product appeared on the drug shortage list in effect under section 506E at any time during the 60-day period ending on the date of the compounding, distribution, or dispensing of the drug product.]
(B) [inserted: The licensed prescriber certifies by notation on the order to the compounding pharmacist or physician that the licensed prescriber has made reasonable attempts to obtain, and has not been able to obtain, to address the urgent medical need a drug product that is compounded by an outsourcing facility in accordance with section 503B with the same active ingredient and the same route of administration.]
(C) [inserted: The compounded drug product is labeled with a beyond-use-date in accordance with applicable United States Pharmacopeia standards.]
(D) [inserted: The licensed pharmacist or licensed physician marks the packaging of the compounded drug product with text—]
(i) [inserted: indicating that the drug product is provided to the hospital or other clinical setting only for urgent administration to a patient; and]
(ii) [inserted: requesting that the hospital or other clinical setting provide to the compounding pharmacist or physician the records that identify the patient or patients to whom the drug products were administered within—]
(I) [inserted: 7 days of each such patient receiving such medication; or]
(II) [inserted: 7 days of each such patient being discharged.]
(E) [inserted: Upon receipt of records requested pursuant to subparagraph (D)(ii), the licensed pharmacist or licensed physician ensures that the patient information in such records is linked with the respective order.]
(F) [inserted: The licensed pharmacist or licensed physician reports adverse events associated with the compounded drug product as soon as possible but not later than 15 days after becoming aware of such events to the MedWatch Adverse Event Reporting program of the Food and Drug Administration (or any successor program).]
(b) Compounded drug
(1) Licensed pharmacist and licensed physician A drug product may be compounded under subsection (a) if the licensed pharmacist or licensed physician—
(A) compounds the drug product using bulk drug substances, as defined in regulations of the Secretary published at section 207.3(a)(4) of title 21 of the Code of Federal Regulations—
(i) that—
(I) comply with the standards of an applicable United States Pharmacopoeia or National Formulary [inserted: drug or dietary supplement ]monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding;
(II) if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary; or
(III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, that appear on a list developed by the Secretary through regulations issued by the Secretary under subsection (c);
§ 353a(b)Compounded drug(1)–(3)
(b)(1)(A)(ii)–(B) unchanged ·
(C) does not compound a drug product that appears on a list published by the Secretary in the Federal Register of drug products that have been withdrawn or removed from the market because such drug products or components of such drug products have been found to be unsafe or not effective; and
(D) does not compound regularly or in inordinate amounts (as defined by the Secretary) any drug products that are essentially copies of a commercially available drug product.
(2) Definition[inserted: .—] [inserted: For purposes of paragraph (1)(D), the term “essentially a copy of a commercially available drug product” does not include—]
(A) [inserted: a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product; or]
(B) [inserted: a drug product that meets each of the following conditions:]
(i) [inserted: At any time during the 60-day period ending on the date of the compounding, distribution, or dispensing, the drug product appeared on the drug shortage list in effect under section 506E.]
(ii) [inserted: If the drug product is not compounded for an identified individual patient based on a valid prescription order or notation, notwithstanding such requirement in the matter preceding paragraph (1) of subsection (a), the drug product—]
(I) [inserted: is labeled in accordance subparagraphs (C) and (D) of subsection (a)(3); and]
(II) [inserted: is documented by the compounding pharmacist or physician in accordance with subparagraphs (E) and (F) of subsection (a)(3).]
[struck: For purposes of paragraph (1)(D), the term “essentially a copy of a commercially available drug product” does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product.]
(3) Drug product A drug product may be compounded under subsection (a) only if—
(A) such drug product is not a drug product identified by the Secretary by regulation as a drug product that presents demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on the safety or effectiveness of that drug product; and
Rest of § 353a unchanged ·
21 U.S.C. § 353b Outsourcing facilities
7 changes the bill asks for here, 6 carried out
- Carried out:
by striking
appears
and insertingappeared
; and - Carried out:
by striking
at the time of
and insertingat any time during the 180-day period ending on the date of
; - Carried out:
in subclause (VIII), by striking the semicolon at the end and inserting
;
and; - Carried out:
by striking subclause (IX); and
- Carried out:
by redesignating subclause (X) as subclause (IX);
- Not carried out:
by redesignating the 2 subsections (d) (relating to definitions and relating to obligation to pay fees) as subsections (e) and (f), respectively; and
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: redesignating the N subsections (X) (relating to definitions and relating to obligation to pay fees) as subsections (X) and (X), respectively; and - Carried out:
by inserting after subsection (c) the following:
(d) List of identified bulk drug substances.— The Secretary shall make publicly available annual updates on the evaluation of bulk drug substances for purposes of the list maintained under subsection (a)(2)(A)(i).;
The section already has a provision under this letter or number, so it would have two.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 353b(a)(2)Bulk drug substances(A)–(C)
Start of § 353b to (a)(2)(A)(i)(II) unchanged ·
(III) publishing a notice in the Federal Register designating bulk drug substances for inclusion on the list; or
(ii) the drug compounded from such bulk drug substance [struck: appears][inserted: appeared] on the drug shortage list in effect under section 356e of this title at [struck: the][inserted: any] time [inserted: during the 180-day period ending on the date ]of compounding, distribution, and dispensing;
(B) if an applicable monograph exists under the United States Pharmacopeia, the National Formulary, or another compendium or pharmacopeia recognized by the Secretary for purposes of this paragraph, the bulk drug substances each comply with the monograph;
(C) the bulk drug substances are each manufactured by an establishment that is registered under section 360 of this title (including a foreign establishment that is registered under section 360(i) of this title); and
§ 353b(a)(10)Labeling of drugs(A)–(B)
(a)(2)(D)–(10)(A) unchanged ·
(VII) storage and handling instructions;
(VIII) the National Drug Code number, if available;[inserted: and]
[struck: (IX)] [struck: the statement “Not for resale”, and, if the drug is dispensed or distributed other than pursuant to a prescription for an individual identified patient, the statement “Office Use Only”; and]
[struck: (X)] [inserted: (IX)] subject to subparagraph (B)(i), a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient.
(B) Container The container from which the individual units of the drug are removed for dispensing or for administration (such as a plastic bag containing individual product syringes) shall include—
(i) the information described under subparagraph (A)(iii)(X), if there is not space on the label for such information;
§ 353b(c)–(d)
(a)(10)(B)(ii)–(c)(3)(B)(i) unchanged ·
(ii) the effective date of the final regulations issued to implement subsection (a)(6).
(4) Updates The Secretary shall review, and update as necessary, the regulations containing the lists of drugs, categories of drugs, or conditions described in subsection (a)(6) regularly, but not less than once every 4 years. Nothing in the previous sentence prohibits submissions to the Secretary, before or during any 4-year period described in such sentence, requesting updates to such lists.
(d) [inserted: List of identified bulk drug substances.—] [inserted: The Secretary shall make publicly available annual updates on the evaluation of bulk drug substances for purposes of the list maintained under subsection (a)(2)(A)(i).]
(d) 2 Definitions In this section:
(1) The term “compounding” includes the combining, admixing, mixing, diluting, pooling, reconstituting, or otherwise altering of a drug or bulk drug substance to create a drug.
Rest of § 353b unchanged ·
21 U.S.C. § 356c Discontinuance or interruption in the production of life-saving drugs
13 changes the bill asks for here, 12 carried out
- Not carried out:
in the section heading, by inserting
OR SURGE IN DEMAND FOR
afterPRODUCTION OF
;“PRODUCTION OF” isn't in § 356c in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“PRODUCTION OF” not found in /us/usc/t21/s356c - Carried out:
by striking
or an interruption of the manufacture of the drug
and inserting, an interruption of the manufacture of the drug, or a surge in demand for the drug
; - Carried out:
by striking
such discontinuance or interruption
and insertingsuch discontinuance, interruption, or surge in demand
; - Carried out:
by striking
the discontinuation or interruption
and insertingthe discontinuation, interruption, or surge in demand
; - Carried out:
by striking
such discontinuation or interruption, the source
and insertingsuch discontinuation, interruption, or surge in demand, the source
; and - Carried out:
by striking
such discontinuation or interruption; the expected duration of the interruption;
and insertingsuch discontinuation, interruption, or surge in demand; the expected duration of the interruption or surge in demand
; - Carried out:
in subsection (b), by striking paragraphs (1) and (2) and inserting the following:
(1) in the case of a notice of a discontinuance or interruption in the manufacture of a drug— (A) at least 6 months prior to the date of the discontinuance or interruption; or (B) if compliance with subparagraph (A) is not possible, as soon as practicable; or (2) in the case of …
- Carried out:
by striking
discontinuance or interruption
and insertingdiscontinuance, interruption, or surge in demand
; and - Carried out:
by inserting
and outsourcing facilities (as defined in section 503B(d))
afterpatient organizations
; and - Carried out:
in paragraph (1), by striking
and that is subject to section 503(b)(1)
and insertingor the active pharmaceutical ingredient of such a drug
; - Carried out:
by amending paragraph (2) to read as follows:
(2) the term “drug shortage” or “shortage”, with respect to a drug, means a period of time with the demand or projected demand for the drug within the United States exceeds the supply of the drug, taking into consideration— (A) how the drug is prepared or dispensed, including …
- Carried out:
in paragraph (3)(B), by striking the period at the end and inserting
; and
; and - Carried out:
by adding at the end the following:
(4) the term “surge” means an increase in demand or projected demand for a drug that the manufacturer likely will be unable to meet without meaningful shortfall or delay..
§ 356c(a)–(e)
Start of § 356c to (a)(1)(B) unchanged ·
(C) intended for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery or any such drug that is critical to the public health during a public health emergency declared by the Secretary under section 247d of title 42; and
(2) that is not a radio pharmaceutical drug product or any other product as designated by the Secretary,
shall notify the Secretary, in accordance with subsection (b), of a permanent discontinuance in the manufacture of the drug [struck: or][inserted: ,] an interruption of the manufacture of the drug[inserted: ,] [inserted: or a surge in demand for the drug ]that is likely to lead to a meaningful disruption in the supply of that drug in the United States, or a permanent discontinuance in the manufacture of an active pharmaceutical ingredient or an interruption in the manufacture of the active pharmaceutical ingredient of such drug that is likely to lead to a meaningful disruption in the supply of the active pharmaceutical ingredient of such drug, and the reasons for such discontinuance[inserted: ,] [inserted: interruption, ]or [struck: interruption][inserted: surge in demand]. Notification under this subsection shall include disclosure of reasons for the discontinuation[inserted: ,] [inserted: interruption, ]or [struck: interruption][inserted: surge in demand], and if applicable, an active pharmaceutical ingredient is a reason for, or risk factor in, such discontinuation[inserted: ,] [inserted: interruption, ]or [struck: interruption][inserted: surge in demand], the source of the active pharmaceutical ingredient and any alternative sources for the active pharmaceutical ingredient known by the manufacturer; whether any associated device used for preparation or administration included in the drug is a reason for, or a risk factor in, such discontinuation[inserted: ,] [inserted: interruption, ]or [struck: interruption][inserted: surge in demand]; the expected duration of the interruption[struck: ;] [inserted: or surge in demand ]and such other information as the Secretary may require.
(b) Timing A notice required under subsection (a) shall be submitted to the Secretary—
(1) [inserted: in the case of a notice of a discontinuance or interruption in the manufacture of a drug—]
(A) [inserted: at least 6 months prior to the date of the discontinuance or interruption; or]
(B) [inserted: if compliance with subparagraph (A) is not possible, as soon as practicable; or]
[struck: at least 6 months prior to the date of the discontinuance or interruption; or]
(2) [struck: if][inserted: in] [struck: compliance][inserted: the] [struck: with][inserted: case] [struck: paragraph][inserted: of] [struck: (1)][inserted: a] [struck: is][inserted: notice] [struck: not][inserted: of] [struck: possible][inserted: a surge in demand for a drug], as soon as practicable.
(c) Distribution To the maximum extent practicable, the Secretary shall distribute, through such means as the Secretary deems appropriate, information on the discontinuance[inserted: ,] [inserted: interruption, ]or [struck: interruption][inserted: surge] [inserted: in demand ]of the manufacture of the drugs described in subsection (a) to appropriate organizations, including physician, health provider, and patient organizations[inserted: and outsourcing facilities (as defined in section 503B(d))], as described in section 356e of this title.
(d) Confidentiality Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5 or section 1905 of title 18.
(e) Coordination with Attorney General Not later than 30 days after the receipt of a notification described in subsection (a), the Secretary shall—
§ 356c(h)–(i)
(e)(1)–(h) unchanged ·
(1) the term “drug”—
(A) means a drug (as defined in section 321(g) of this title) that is intended for human use [struck: and][inserted: or] [struck: that][inserted: the] [struck: is][inserted: active] [struck: subject][inserted: pharmaceutical] [struck: to][inserted: ingredient] [struck: section 353(b)(1) ]of [struck: this][inserted: such] [struck: title][inserted: a drug]; and
(B) does not include biological products (as defined in section 262 of title 42), unless otherwise provided by the Secretary in the regulations promulgated under subsection (i);
(2) [inserted: the term “drug shortage” or “shortage”, with respect to a drug, means a period of time with the demand or projected demand for the drug within the United States exceeds the supply of the drug, taking into consideration—]
(A) [inserted: how the drug is prepared or dispensed, including the route of administration and dosage form; and]
(B) [inserted: information reported by manufacturers, health care professionals, and patients;]
[struck: the term “drug shortage” or “shortage”, with respect to a drug, means a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug; and]
(3) the term “meaningful disruption”—
(A) means a change in production that is reasonably likely to lead to a reduction in the supply of a drug by a manufacturer that is more than negligible and affects the ability of the manufacturer to fill orders or meet expected demand for its product; and
(B) does not include interruptions in manufacturing due to matters such as routine maintenance or insignificant changes in manufacturing so long as the manufacturer expects to resume operations in a short period of time[struck: .][inserted: ; and]
(4) [inserted: the term “surge” means an increase in demand or projected demand for a drug that the manufacturer likely will be unable to meet without meaningful shortfall or delay.]
(i) Regulations
(1) In general Not later than 18 months after July 9, 2012, the Secretary shall adopt a final regulation implementing this section.
Rest of § 356c unchanged ·